Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Geron raises $100 million for pipeline development

This article was originally published in Scrip

Executive Summary

The gross proceeds from Geron's public offering this week have reached $100 million following the underwriters' decision to exercise in full their option to purchase an additional 2.6 million shares of common stock at the public offering price of $5.00 per share. Geron said earlier this week that it would offer just under 17.4 million shares, excluding the over-allotment option. The company's share price closed 18% down at $5.00 on 7 December following news of the stock dilution.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC011070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel